Overview

• On July 15, 2025, the Global Neurodegeneration Proteomics Consortium released anonymized data from nearly 40,000 patient and control samples, comprising over 300 million protein analyses freely available to researchers.
• Initial findings published in Nature Medicine and Nature Aging reveal that the APOE4 variant functions as a pleiotropic modulator of immune-driven neuroinflammation across Alzheimer’s, Parkinson’s, ALS and frontotemporal dementia.
• Despite shared inflammatory pathways, each disease exhibits a distinct proteomic signature, enabling the development of targeted predictive models for individual pathologies.
• The consortium’s harmonized dataset builds on contributions from 23 institutions across the US, Europe and Australia, with funding from Johnson & Johnson and Gates Ventures.
• GNPC aims to recruit more institutions and incorporate at least 10,000 additional samples to bolster early-detection biomarkers and expedite therapy development.